SCHEMBL18173872

SCHEMBL18173872

Cc1nc2cc(N(C)C(=O)[C@@H](N)Cc3cc(F)cc(F)c3)ccc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TRPV1 Q8NER1 2/20 0.36
GAA P10253 1/20 0.35
DYRK1A Q13627 2/20 0.35
POLB P06746 1/20 0.35
P2RX7 Q99572 1/20 0.35
CLK1 P49759 1/20 0.34
CLK2 P49760 1/20 0.34
CIT O14578 1/20 0.34
LGALS3 P17931 1/20 0.33
LDHA P00338 1/20 0.33
CASP3 P42574 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18173873 1.00 ALDH1A1 (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL21992599 0.90 DYRK1A (0.35) ALDH1A1NPC1RAB9AMAPTGAA
SCHEMBL19969184 0.90 DYRK1A (0.35) ALDH1A1NPC1RAB9AMAPTGAA
SCHEMBL18180208 0.83 MAPT (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL16669966 0.82 CIT (0.36) NPC1RAB9ADYRK1ACLK1CLK2
SCHEMBL16669965 0.82 CIT (0.36) NPC1RAB9ADYRK1ACLK1CLK2
SCHEMBL18179808 0.80 CLK1 (0.33) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL18180340 0.80 CTSS (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL18179939 0.80 TRPM5 (0.39) DYRK1ACLK1CLK2CIT
SCHEMBL18180362 0.80 ALDH1A1 (0.35) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286166-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2020-05-13 EP disclosed
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed
EP-3286166-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-02-28 EP disclosed
WO-2016172424-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-27 WO disclosed
WO-2016172425-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H ALDH1A1 2912/4885NPC1 209/4885RAB9A 1558/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H ALDH1A1 2912/4885NPC1 209/4885RAB9A 1558/4885
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E ALDH1A1 2545/4885NPC1 273/4885RAB9A 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.